Barrett’s-related esophageal adenocarcinoma: Is chemoprevention a potential option?

M. Brian Fennerty, George Triadafilopoulos

Research output: Contribution to journalReview article

29 Scopus citations

Abstract

OBJECTIVE: Review the rationale behind secondary prevention of Barrett’s related esophageal adenocarcinoma and critically appraise the emerging literature regarding prevention of neoplasia in Barrett’s esophagus with antisecretory and/or cyclo-oxygenase inhibition therapy. METHODS: The existing English language literature regarding secondary cancer prevention in patients with Barrett’s esophagus is reviewed and its potential clinical implications discussed. RESULTS: There is biologic plausibility to pursue “chemo-prevention” trials with antisecretory and/or cyclo-oxygenase inhibition therapy in patients with Barrett’s esophagus. CONCLUSION: Chemoprevention trials using potent antisecretory therapy coupled with cyclo-oxygenase 2 inhibition are warranted and may provide a means of decreasing the occurrence of cancer and cancer-related mortality in this disease.

Original languageEnglish (US)
Pages (from-to)2302-2305
Number of pages4
JournalAmerican Journal of Gastroenterology
Volume96
Issue number8
DOIs
StatePublished - Aug 2001

    Fingerprint

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this